Digoxin requesting patterns were studied prospectively over a 6-month period. Clinicians were not forewarned that the study was being undertaken. Many samples received in the laboratory were taken at incorrect times after the drug had been given. This led to inappropriate action being taken in some cases. Appropriate action was taken on most patients who had toxic serum digoxin levels together with clinical signs. The role of subtherapeutic digoxin levels seems unclear as these elicit a wide variety of responses.
The value of assaying serum digoxin concentrations has been the subject of a number of publications recently.!" Furthermore. the indications for digoxin therapy are themselves under question."
Nevertheless. digoxin assays are commonly requested by clinicians and since the clinical signs of toxicity may be non-specific (anorexia, nausea, vomiting. confusion). laboratories feel a commitment to continue to provide measurements. Additionally. the therapeutic range for digoxin is unclear. Whilst most therapeutic concentrations are quoted to be in the range 1·3-2·6 nmol/L lower concentrations may suffice."
Faced with these facts, we decided to initiate a prospective study to investigate the pattern of requesting and response to results over a 6-month period. No prior notification of this study was given to clinical staff.
Materials and methods
During the first 6 months of lY86, 877 samples for digoxin assay were received. All samples were assayed for digoxin using the Abbott TDx system (Abbott Laboratories Ltd. Esher, Surrey, UK). 408 time. clinical evidence of toxicity and any action taken were requested if not already provided on the request form. In a few cases it was not possible to obtain all the required details and these patients were regarded as lost to followup.
Results
Eight hundred and seventy-seven samples from 517 patients were received over the 6-month period. 72·7"/" were in-patient samples. 20·2'X, were hospital out-patient samples and the remaining samples (7,1 'Y,,) were from general practitioner (OP) patients. Figure I shows the classification of samples according to digoxin concentration. Table I shows the classification of samples with digoxin concentrations greater than 2·6 nmollL according to timing of dosc and action taken on result. Overall. 47 (42'3%) of these samples must be considered as inappropriate due to the incorrect time of sampling or absence of details necessary for proper interpretation of the result. Of the remaining 64 samples. nearly half (47·4%) were associated with clinical evidence of toxicity. Clinical action was taken in most cases where both clinical and laboratory findings suggested toxicity. In one case no action was taken on combined evidence of toxicity; and in one case action was taken on laboratory findings alone. Two hundred and eighty-nine samples were found to have digoxin concentrations below the therapeutic range. Indications for sampling and clinical action Table 2 . 'No action' signifies no apparent scrutiny of thc result hy clinical staff. This Was particularly frequent for samples from out-patient clinics. One sample was subsequently found to have been taken from a patient on rnedigoxin. 
Discussion
The value of monitoring digoxin concentrations is currently controversial. I-{) Major deficiencies in the area are due to the lack of a consistent correlation between plasma digoxin concentrations and pharmacological effect. and the practical problem of specimens drawn under non steady-state conditions. The latter was particularly evident in this study which is in striking contrast to the findings of Bonati et al. 2 and may reflect differing awareness of the problem by clinicians. Of more concern perhaps was the fact that action was taken on a number of incorrectly timed specimens with digoxin concentrations above the therapeutic range.
On a number of occasions it proved impossihle to obtain details relating to dose and sample time either from the case notes or from the requesting clinician. This emphasises the lack of awareness regarding steady-state conditions.
In the study presented we have attempted to achieve a realistic audit of a therapeutic monitoring service over a 6-month period. In order to maintain as near normal requesting patterns as possible. clinicians were not given prior warning about the study. In a short 12-week study" of only in-patient samples. in which the clinicians were given prior warning of the study. similar findings were obtained.
The significance of digoxin concentrations in the sub-therapeutic range seems to be unclear as evidenced hy the variety of subsequent actions ranging from increasing to reducing the dose of digoxin. It is certainly true that different individual clinical responses may be appropriate for the individual needs of the patient, depending on the indication for sampling. However, it would appear that many requests were made on a random basis.
One request was made for digoxin assay in a patient receiving medigoxin. This drug is not measured by the Abbott TDx method and it is fortunate that the request form was appropriately completed noting the drug being given. The potential for error is obvious; the low 'digoxin' result prompted the physician to increase the dose to try and achieve a result in the therapeutic range for digoxin.
There is considerable confusion regarding the rationale for digoxin requesting and this has major revenue implications. Two way exchange of information is essential in this area if a costeffective service is to be provided. It is pointless for the laboratory to complain that insufficient details have been provided on the request form for interpretation of the result if they fail to alert the clinician to analytical problems such as the inability of the Abbott TDx system to measure medigoxin. Baillie and Angaran suggest that clinical pharmacists should provide this two way exchange of information. ' We would add that in many hospitals the drug monitoring service is based in the clinical chemistry laboratory and that input from this area is no less valuable.
Despite the problems encountered. it is evident that decisions about the management of patients arc made on the combined evidence of clinical suspicion and serum concentration. This would imply that there is indeed a role for appropriate digoxin monitoring.
